Novartis Pharmaceuticals UK and NHS Ayrshire & Arran have announced the launch of a new facility designed specifically for people suffering from some of the most common forms of avoidable sight loss.

Based in University Hospital Ayr, Scotland, the facility is set to support the delivery of a one-stop clinic for patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The new facility is expected to transform the patients’ eye service by building an extension on to the existing Ophthalmology Outpatient Department.

University Hospital Ayr consultant ophthalmologist Dr Mohan Varikkara said: “The new extension is a much welcome addition to our busy service. We know the numbers of people requiring macular treatment is increasing as people are living longer.

"By utilising an outcomes-based approach, we are able to deliver greater accessibility and sustainability of care for patients."

“This new extension and additional staff will ensure we are able to treat more patients and offer us the ability to provide an intravitreal therapy service that prevents eye degeneration and potential sight loss.”

See Also:

The companies have carefully planned to design requirements of this new facility to create a comfortable environment for patients and staff.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary focus was on accessibility, patient flow throughout the clinic and improving patient experience, particularly for visually impaired people.

Novartis Pharmaceuticals UK managing director and chief scientific officer Dimitrios Georgiopoulos said: “This partnership is part of Novartis’ ongoing commitment to work with the NHS to understand and address the challenges facing eye care services across the UK.

“By utilising an outcomes-based approach, we are able to deliver greater accessibility and sustainability of care for patients.”